We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Voglibose Reduces Arterial Stiffness through Lowering Postprandial Hyperglycemia in Obese Type 2 Diabetes.
- Authors
Satoh, Noriko; Shimatsu, Akira; Yamada, Kazunori; Ogawa, Yoshihiro
- Abstract
Recent epidemiological studies such as DECODE/DECODA Study and Funagata Diabetes Study have revealed that postprandial hyperglycemia is an independent risk factor and is a more powerful predictor of atherosclerosis and cardiovascular disease (CVD) and mortality than fasting plasma glucose (FPG). Pulse Wave Velocity (PWV), a direct parameter of arterial distensibility, is widely used as a noninvasive marker for evaluating atherosclerosis. This study was designed to elucidate whether improving postprandial state by voglibose, an α-glucosidase inhibitor, leads to the reductions of systemic inflammation and PWV in obese type 2 diabetic patients. A total of 40 Japanese obese type 2 diabetic patients (12 men and 28 women, mean age 55.6 ± 1.9 years, mean BMI 29.8 ± 0.7 kg/m², mean HbA1c 7.5 ± 0.2%) were randomly assigned to one of the following treatment groups; they were treated for 6 months with either diet alone (diet group) (n = 20) or diet plus voglibose (0.9 mg daily) (voglibose group) (n = 20). Postprandial PG (PPG) levels were examined 2h after the conventional breakfast. The changes in glycolipid parameters, hsCRP and PWV were monitored before and 3 weeks, 6 months after the voglibose treatment. Analysis of diurnal metabolic profiles revealed that treatment with voglibose for 3 weeks significantly reduced FPG, PPG, C-peptide, HOMA-R, apolipoprotein B (ApoB), ApoE, and triglycerides (TG) relative to the diet group (P < 0.05). The voglibose treatment for 3 weeks also decreased significantly plasma level of high sensitivity CRP (hsCRP), a marker of inflammation (P < 0.01). After treatment with voglibose for 6 months, FPG, PPG, HbA1c, IRI, HOMA-R, TG and hsCRP were reduced and HDL-C was increased significantly relative to the diet group (P < 0.05), despite similar improvement of BMI in both groups. Voglibose also decreased significantly PWV relative to the control group (diet group, 1460 ± 40 → 1490 ± 44 cm/s; voglibose group, 1492 ± 46 → 1400 ± 40 cm/s, P = 0.004). Reduction of PWV for 6 months by voglibose correlated with decreases in FPG, and PPG for 6 months (FPG, P = 0.037; PPG, P = 0.006). By stepwise multiple regression analysis using the metabolic variables (r² = 0.12), the reduction of PWV were significantly correlated with only the decrease of PPG (F = 8.45, P = 0.006). This study represents the first demonstration that voglibose reduces systemic inflammation and arterial stiffness by improving postprandial state in obese type 2 diabetic patients, which may contribute to the reduction of the risk of CVD.
- Publication
Diabetes, 2007, Vol 56, pA173
- ISSN
0012-1797
- Publication type
Academic Journal